
    
      Subjects enrolled in the R1500-CL-1331 clinical trial (NCT0226595) will participate in a
      study visit before and after administration of the ANGPTL3 inhibitor REGN1500, evinacumab)
      for the evaluation of its effect on lipoprotein kinetics.
    
  